Industry / innovation partners

AI can flag hidden cardiac risk. The dangerous part is what health systems do next

Metabolic syndrome may leave a signature in mitochondrial DNA. The biomarker race should not outrun the evidence

Breast Cancer Gets a New PI3K Pathway Option.

Bladder Cancer Surgery Just Became a System Test

Down Syndrome Cannot Stay Outside Alzheimer’s Trials

AstraZeneca’s heart drug failure raises a brutal question: how much treatment is too much treatment?

A Blood Test Will Not Fix Colorectal Screening by Itself

Radioligand Therapy Is Building Its Evidence Base. Now Build the Infrastructure.

Tau Is Back. Certainty Is Not.
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
